US Edition
News from Medscape
We’ve assigned a media bias rating of unknown to Medscape. You can read more about our methodology here.
Information about Medscape
Where is Medscape located?United StatesMedscape's WebsiteMedscape's TwitterMedscape's WikipediaMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Medscape News
Health · United StatesBy Sandee LaMotte, CNN (CNN) — People who consumed the highest levels of certain artificial sweeteners — equivalent to just one diet soda a day — saw a significant decline in their ability to remember and recall words when compared to people who consumed the lowest levels, a new study found. “People who consumed the most low- or no-calorie sweeteners showed a 62% faster global cognitive decline than those who consumed the lowest amount — that’s …See the Story
Artificial sweeteners aged the brain by over 1.5 years, study says
67% Center coverage: 48 sources
ResearchA new Mayo Clinic study finds that many heart attacks in people under 65 - especially women - are caused by factors other than clogged arteries, challenging long-standing assumptions about how heart attacks occur in younger populations.See the Story
Heart Attacks in Women Under Age 65 Are Caused by Factors Other than Clogged Arteries
83% Center coverage: 6 sources
Johnson & JohnsonFinal overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).See the Story
Osimertinib Plus Chemotherapy Offers Overall Survival Advantage for Patients with EGFR-Mutated Advanced NSCLC
100% Center coverage: 4 sources
